BUSINESS

White House Announces Largest Drug Pricing Deals Yet

PUBLISHED Dec 19, 2025, 2:36 PM ET

Read, Watch or Listen

White House Announces Largest Drug Pricing Deals Yet

Media Bias Meter

Sources: 10

Center 70%

Right 30%

Sources: 10

WASHINGTON — The Trump administration announced agreements with nine drugmakers to lower U.S. prescription prices and expand domestic manufacturing. Companies pledged to cut Medicaid prices to levels paid in peer nations, launch new drugs at comparable global prices, and distribute discounts through a TrumpRx platform. The deals raised the total to 14 firms and include donations of bulk active pharmaceutical ingredients to a national reserve — Merck (ertapenem), Bristol Myers Squibb (apixaban) and GSK (albuterol). Three targeted firms have not yet signed. Agreements link price cuts to tariff relief and reshoring incentives. Per reports. Based on 6 articles reviewed and supporting research.

By Shahbaz A. | JQJO News

Timeline of Events

Summer: Administration identified and targeted 17 drugmakers for pricing negotiations.
Earlier this year: Several companies (including Pfizer and AstraZeneca) struck initial price-reduction agreements.
Dec 20: White House announced nine additional company agreements, bringing total signatories to 14.
Dec 20: Some signatories pledged donations of bulk active ingredients to a Strategic API Reserve.
Dec 20: Administration linked price concessions to tariff relief and announced a planned TrumpRx consumer discount platform.

Media Bias

Articles Published:: 10
Right Leaning:: 3
Left Leaning:: 0
Neutral:: 7
Distribution:: Left 0%, Center 70%, Right 30%

Who Benefited

Immediate beneficiaries include Medicaid enrollees receiving lower-priced medicines, patients accessing discounted drugs through the planned TrumpRx platform, and U.S.-based manufacturers and suppliers receiving incentives tied to reshoring and tariff relief.

Who Impacted

Potentially harmed parties include multinational drugmakers facing compressed U.S. prices, international suppliers exposed to global price benchmarking, and market segments dependent on previous higher U.S. revenues that may face margin pressure.